Recent works of Hanfstein et al. 10 and Marin et al. 11 proved that the 3rd month BCR-ABL transcript level higher than 10% IS was significantly predictive of survival without progression (i.e., survival without evidence of AP or BC or death from any cause during IM therapy) on IM first line. This evidence concerns the gene ABL1 and breast cancer.